人人干人人摸人人骑-人人干人人澡-人人干天天搞夜夜爽-人人干综合-人人搞人人摸-人人搞人人模

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Enhanced T Cell Platforms

Enhanced T Cell Platforms (HyperTCell ®), including HyperCART® , are mainly to solve the global highlighted problem in solid tumor therapy through genetic modification of T cells. HyperCART® takes improving the clinical efficacy of CAR-T in solid tumors as its core purpose. Based on the concept of synthetic biology, HyperCART® adopts efficient gene delivery system to target tumor cells specifically, reverse the immuno suppressive state and improve the predicament of difficult infiltration and poor efficacy of traditional CAR-T in solid tumor therapy. 


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 国产偷窥熟妇高潮呻吟 | 天天干夜夜爱 | 中文字幕在线不卡一二 | 日本乱码视频中文字幕 | 精品久久久久久午夜福利 | 午夜拍国产精品福利 | 国产人人干 | 国产成人高清在线观看播放 | 国产情侣激情视频无码 | 日韩经典| 国产精品不卡一区 | 99久久精品无码专区免费 | 日韩欧美精品一区二区三区 | 岛国三级 | 色欲色欲日韩www在线观看 | 午夜无码视频一区二区三区 | 91最新精 | 国产热门视频在线播放 | 久久国产精品久久久久久久久久 | 亚亚洲国产视频 | 国产一区美女自慰喷水 | 狠狠操 狠狠干 | 国语自产偷拍精品视 | 亚洲AV无码一区二区三区性色 | 在线一区二区 | 男女做爰全A片免费看 | 日本a∨精品一区二 | 91大视频网站 | 91偷偷| 三级在线看中文字 | 91精品久久香蕉国产线看 | 国产香蕉久久精品 | 成人影片一二三区在线观看 | 国产舌乚八伦偷品w中 | 精品在线观看免费 | 精品无码一二区A片卡不 网站 | 国产第十三页激情自拍 | 国产一级毛片女人高潮水真多 | 国产精品天干天干在线下载 | 亚洲性之站 | 亚洲国产另类在线 |